+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
144.3000
2.5348
2.4823
.0580
1.7553
4.7685
Low
77.5390
7.6343
No
No
Yes
No
Yes
No
0.6
No
No
Yes
No
Methyllycaconitine citrate (MLA citrate) is a natural product derived from plants, attracting attention for its unique regulatory effects on the nervous system. As a potent and highly selective α7-type nicotinic acetylcholine receptor (α7nAChR) competitive antagonist, MLA citrate holds an important position in neuropharmacological research. α7nAChR is widely distributed in the central nervous system and participates in various physiological functions such as cognition, memory, inflammation regulation, and neuroprotection. Its abnormal functions are closely related to various neurological diseases. MLA citrate is an important molecular molecule for studying disease mechanisms such as Alzheimer's disease (AD), neuroinflammation, and neurotoxicity due to its ability to cross the blood-brain barrier and its high selectivity for α7nAChR.
In recent years, multiple studies on MLA citrate in cell and animal models have shown that this compound not only mitigates neurotoxicity induced by amyloid β peptide (Aβ), but also prevents methamphetamine damage to the mouse striatum, demonstrating its potential neuroprotective effects. In addition, the role of MLA citrate in regulating pain perception and neuroinflammation has gradually been revealed, involving multiple ion channels and neurotransmitter receptors. This paper will systematically review the chemical structure, pharmacological activity, mechanism of action, druggability evaluation, and prospects for application of MLA citrate in neurological diseases, aiming to provide a theoretical foundation and practical guidance for research in related fields.
Methyl citrate cow bicarbonate is a complex alkaloid compound with a molecular weight of 682.8110, reflecting its polycyclic structure and abundant functional groups. The structural core of MLA citrate is methyllycaconitine, whose molecules contain multiple cyclic structures and ester groups. The citrate form imparts a certain degree of water solubility and stability. The compound had a LogP value of 2.5348, indicating moderate lipid solubility, which helps penetrate cell membranes and the blood-brain barrier. The topological polar surface area (TPSA) is 144.3 Ų, reflecting the number of polar groups. A higher TPSA value is usually associated with lower passive diffusion capacity, but MLA citrate can still effectively cross the blood-brain barrier, possibly due to its specific molecular conformations and receptor-mediated transport mechanisms.
The water solubility is 0.0580, indicating a relatively low solubility in water, but improved water solubility through the citrate form. The hERG channel inhibition test was negative, indicating a low cardiotoxicity risk for this compound. The Ames test result was 0.6, indicating a low genotoxicity risk and meeting safety requirements. In summary, MLA citrate possesses excellent physicochemical properties, laying the foundation for its pharmacological activity and druggability.
Methyl alkaloids are mainly found in Aconitum species, especially in Aconitum lycoctonum and related species. MLA citrate, as the citrate form of methyl cow flatalkalis, is usually prepared by further purification after plant extraction. Traditional extraction methods include alcohol extraction, acid-base separation, and column chromatography purification.
The typical extraction process is: first, ethanol or methanol is used for reflux extraction of dried plant material. After concentration, the extract is adjusted with acidic aqueous solution to adjust pH to promote the formation of alkaloid salts. Then, non-polar impurities are removed by liquid-liquid extraction, followed by column chromatography (such as silica gel columns and C18 reversed-phase columns) to separate and purify the target compounds. Ultimately, the water solubility and stability are improved through a citrate salting reaction to obtain MLA citrate. Modern technologies such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) are widely used for extract identification and purity testing.
In recent years, with the development of synthetic methods, the full synthesis route of MLA citrate has gradually been reported, making large-scale preparation and structural modification possible, and promoting its application in pharmacological research.
As a high-affinity competitive antagonist of α7nAChR, MLA citrate's pharmacological activity mainly lies in selective blockade of this receptor. α7nAChR is a highly permeable calcium channel that mediates rapid neurotransmitter transmission and neuromodulation. MLA citrate blocks the binding of acetylcholine or other agonists by occupying receptor binding sites, inhibiting receptor activation, and regulating neuronal excitability and downstream signaling pathways.
This action makes MLA citrate an important tool for studying α7nAChR function, especially in models of neuroinflammation, cognitive impairment, and neurodegenerative diseases. Relevant studies have shown that MLA citrate can significantly reduce Aβ-induced SH-SY5Y neurotoxicity, suggesting its potential intervention role in the pathological mechanisms of Alzheimer's disease.
MLA citrate demonstrated neuronal protection in animal models. For example, in a methamphetamine-induced mouse striatum injury model, MLA citrate pretreatment significantly reduced neurotoxicity and improved neurological function. This effect may be related to its regulation of α7nAChR-mediated neuroinflammation and excitotoxicity.
Additionally, MLA citrate has been reported to regulate neuroinflammatory responses, possibly alleviating chronic inflammation in the nervous system by inhibiting microglial activation and inflammatory factor release.
Although MLA citrate mainly targets α7nAChR, its role in analgesic mechanisms has also attracted attention. Analgesia-related targets include TRPV1, CNR1, OPRD1, PTGS1, TRPA1, PTGS2, SLC6A4, OPRM1, OPRK1, and DRD2. MLA citrate may indirectly affect these pathways by regulating neurotransmitter release and receptor activity, exerting analgesic effects. Related research is deeply exploring its potential applications in chronic pain and neuropathic pain.
The main mechanism of action of MLA citrate is based on its competitive antagonism to α7nAChR. α7nAChR is a ligand-gated ion channel widely distributed in neurons and immune cells, regulating calcium ion influx and intracellular signaling. Activation of this receptor is involved in regulating neuroprotection, cognitive function, and inflammatory responses.
MLA citrate binds to the acetylcholine-binding site of α7nAChR, blocking receptor activation and inhibiting calcium influx, thereby regulating downstream signaling pathways such as PI3K/Akt, MAPK, and NF-κB. This regulation helps reduce neuroinflammation, inhibit apoptosis, and decrease oxidative stress.
Additionally, MLA citrate influences the release of inflammatory mediators and neuronal excitability by regulating interactions between neurons and glial cells. Its indirect regulation of pain-related receptors and channels also provides a molecular basis for its analgesic effects.
From the perspective of druggability, MLA citrate offers multiple advantages. Although its molecular weight of 682.8 is relatively large, its moderate lipid solubility (LogP 2.53) and high polarity (TPSA 144.3) make it excellent for blood-brain barrier penetration, making it suitable for central nervous system drug development. Although water-soluble is relatively low, the citrate form improves its solubility and bioavailability.
In terms of safety, MLA citrate does not inhibit hERG channels, reducing the risk of cardiotoxicity. Ames test results showed that its genotoxicity risk is low and meets drug safety requirements. Pharmacokinetic data are still limited, but existing studies have shown that both oral and injectable doses can achieve effective brain tissue concentrations with moderate half-lives, making them suitable for further development.
In the future, further systematic evaluation of its metabolic pathways, distribution in vivo, and excretion characteristics is needed to optimize administration regimens and formulation design.
MLA citrate, as a selective antagonist of α7nAChR, has broad application prospects in neurological diseases. As a typical disease with α7nAChR dysfunction, MLA citrate may delay cognitive decline by alleviating Aβ-induced neurotoxicity. Moreover, its regulatory effects on neuroinflammation and neurotoxicity offer new approaches for treating Parkinson's disease, schizophrenia, and drug dependence.
In the field of analgesia, MLA citrate modulates through multiple targets and may become a novel drug candidate for treating chronic and neuropathic pain. Its excellent safety and central penetration give it strong clinical translation potential.
Future research should focus on preclinical pharmacological and toxicological evaluation, formulation optimization, and clinical trial design of MLA citrate, exploring its specific efficacy and safety in neurodegenerative diseases, psychiatric disorders, and pain management, and promoting its effectiveness as an effective drug in clinical practice.
Methyl catrylium citrate, as a naturally distinctive and functionally significant product, demonstrates great potential in basic research and drug development for neurological diseases due to its highly selective antagonism of α7nAChR. Its multiple pharmacological activities—including neuroprotection, anti-inflammation, and analgesia—provide new targets and strategies for treating Alzheimer's disease and related neurological disorders. Although research into its pharmacokinetics and clinical applications is still in its early stages, with advances in synthesis technology and pharmacological research, MLA citrate is expected to become an important drug molecule in the future field of neuropharmacology. Ongoing and systematic research will lay a solid foundation for clinical translation, driving the development and innovation of natural product pharmacology.
Shenshuai
Wenjing
Hedandan
